SEC Filing Analysis: Guardant Health, Inc. (GH)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director executed a pre-planned, very small sale of common stock, representing an insignificant portion of their holdings and having no material impact on the company.
• Market Impact: Neutral. The transaction is too small to influence market sentiment or stock price.

Company Information

Field	Value
Company	Guardant Health, Inc.
Ticker Symbol	GH
CIK	0001576280
Industry	SERVICES-MEDICAL LABORATORIES

Insider Information

Field	Value
Name	POTTER MYRTLE S
CIK	0001214130
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-17
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	26
Price Per Share	$66.95
Total Value	$1,740.70
Shares Owned After	18,324
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,740.70
% of Market Cap	0.000021%
Shares Transacted	26
% of Shares Outstanding	0.000021%
Post-Transaction Ownership	18,324 shares (0.015% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction value of $1,740.70 is negligible against Guardant Health's $8.16 billion market capitalization. It falls far below any threshold for market significance.
• Ownership Concentration: The director's post-transaction ownership of 18,324 shares constitutes a very small fraction (0.015%) of the total shares outstanding. The sale of 26 shares represents only 0.14% of the director's prior holdings, indicating no significant change in their investment position.
• Dilution Impact: Not applicable as this is a sale of existing shares, not an issuance of new equity.
• Transaction Significance: The transaction is objectively rated as having low significance. The value is less than 0.1% of the market cap, and the shares involved are less than 0.1% of the outstanding shares. The pre-scheduled nature of the sale further diminishes its importance as a market signal.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is de minimis. It is far too small in both absolute dollar value and relative to the company's market size to have any impact on the stock price. Automated trading algorithms and institutional investors would likely filter out a trade of this size as noise.

Volume & Sentiment

• Expected Volume Impact: None. The transaction size is a tiny fraction of daily trading volume.
• Sentiment Indicator: Neutral. The sale is too small to be considered bearish, especially given it was conducted under a 10b5-1 plan.

Investment Insights

Positive Market Indicators

• No positive indicators can be derived from this filing.

Risk Factors

• No new risk factors are indicated by this minor transaction.

Key Takeaways

1. Immaterial Transaction: The sale of 26 shares for ~$1,741 is insignificant for a multi-billion dollar company.
2. Pre-Planned Sale: The filing notes this transaction was made pursuant to a Rule 10b5-1 trading plan, meaning it was scheduled in advance and is not a reaction to current events.
3. No Change in Conviction: The sale represents a tiny fraction (0.14%) of the director's holdings, implying no change in their long-term conviction in the company.

Additional Context

Transaction Notes

• Special Circumstances: The transaction was executed under a Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations. This context is crucial as it detaches the trade from any potential non-public information the insider might possess.
• Market Environment: The trade should be viewed as routine portfolio management or for personal liquidity purposes by the insider, rather than a strategic financial move.